Our top pick for
Sesen Bio Inc is a biotechnology business based in the US. Sesen Bio shares (SESN) are listed on the NASDAQ and all prices are listed in US Dollars. Sesen Bio employs 27 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$1.27|
|52-week range||$0.73 - $5.03|
|50-day moving average||$0.88|
|200-day moving average||$2.63|
|Wall St. target price||$2.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.82|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||32.60%|
|1 month (2021-09-22)||59.47%|
|3 months (2021-07-22)||-68.56%|
|6 months (2021-04-22)||-49.80%|
|1 year (2020-10-21)||6.72%|
|2 years (2019-10-21)||6.72%|
|3 years (2018-10-19)||1.62|
|5 years (2016-10-21)||2.31|
|Revenue TTM||$17.8 million|
|Gross profit TTM||$-17,955,000|
|Return on assets TTM||-11.29%|
|Return on equity TTM||-507.57%|
|Market capitalisation||$187.7 million|
TTM: trailing 12 months
There are currently 7.7 million Sesen Bio shares held short by investors – that's known as Sesen Bio's "short interest". This figure is 49.6% down from 15.2 million last month.
There are a few different ways that this level of interest in shorting Sesen Bio shares can be evaluated.
Sesen Bio's "short interest ratio" (SIR) is the quantity of Sesen Bio shares currently shorted divided by the average quantity of Sesen Bio shares traded daily (recently around 12.6 million). Sesen Bio's SIR currently stands at 0.61. In other words for every 100,000 Sesen Bio shares traded daily on the market, roughly 610 shares are currently held short.
However Sesen Bio's short interest can also be evaluated against the total number of Sesen Bio shares, or, against the total number of tradable Sesen Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sesen Bio's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Sesen Bio shares in existence, roughly 40 shares are currently held short) or 0.0391% of the tradable shares (for every 100,000 tradable Sesen Bio shares, roughly 39 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sesen Bio.
Find out more about how you can short Sesen Bio stock.
We're not expecting Sesen Bio to pay a dividend over the next 12 months.
Over the last 12 months, Sesen Bio's shares have ranged in value from as little as $0.728 up to $5.03. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sesen Bio's is 0.5302. This would suggest that Sesen Bio's shares are less volatile than average (for this exchange).
Sesen Bio, Inc. , a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of BCG-unresponsive NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.